Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 30 May, 2024|Author: Getaka | Social: X Twitter Profile
Stock Ticker - BSE: 506197 | NSE: BLISSGVS

Fundamental Analysis of Bliss GVS Pharma Ltd

Basic Stock Data

Last Updated: April 17, 2024, 1:09 pm

Market Cap 1,175 Cr.
Current Price 112
High / Low150/70.8
Stock P/E13.4
Book Value 88.8
Dividend Yield0.45 %
ROCE11.8 %
ROE8.30 %
Face Value 1.00
PEG Ratio-5.98

Competitors of Bliss GVS Pharma Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
Kopran Ltd 1,137 Cr. 236292/14122.3 1021.27 %13.8 %11.0 % 10.0
Chandra Bhagat Pharma Ltd 83.6 Cr. 111160/80.071.5 37.30.00 %7.13 %3.36 % 10.0
Themis Medicare Ltd 1,929 Cr. 210266/13144.3 41.00.24 %13.9 %12.1 % 1.00
Sequent Scientific Ltd 2,734 Cr. 110156/71.6 26.30.00 %0.90 %2.46 % 2.00
J B Chemicals & Pharmaceuticals Ltd 26,042 Cr. 1,6791,940/95847.1 1880.53 %25.1 %20.4 % 1.00
Industry Average6,385.12 Cr469.2037.0478.920.41%12.17%9.86%4.80

Bliss GVS Pharma Ltd Quarterly Results

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales164132168196216167189172206185160212201
Expenses126115134167182147150148158179135158157
Operating Profit3817352934203925486245444
OPM %23%13%21%15%16%12%21%14%23%3%15%26%22%
Other Income4685-681272635135
Interest1211122215112
Depreciation4444445555667
Profit before tax37173730-3926392047-1225940
Tax %26%51%29%26%-25%11%30%21%37%561%34%27%27%
Net Profit2882622-49232716303144329
EPS in Rs2.480.602.352.05-4.831.892.481.332.680.321.414.052.64

Quarterly Chart

Bliss GVS Pharma Ltd Profit & Loss

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales267397345407547798815899689577747752762
Expenses196285273304391596618739566471629634629
Operating Profit7111171103156203197160123107118117132
OPM %27%28%21%25%29%25%24%18%18%18%16%16%17%
Other Income161428202412-8352620-421826
Interest41018161920234865109
Depreciation46111113202191317171922
Profit before tax79109719614817514518212910454106127
Tax %34%46%42%36%32%36%39%30%26%29%57%28%
Net Profit53604161100113891279574237791
EPS in Rs5.095.603.975.818.007.955.7011.999.436.641.456.808.46
Dividend Payout %15%12%13%12%6%8%18%8%5%8%34%7%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)13.21%-31.67%48.78%63.93%13.00%-21.24%42.70%-25.20%-22.11%-68.92%234.78%
Change in YoY Net Profit Growth (%)0.00%-44.87%80.45%15.15%-50.93%-34.24%63.94%-67.89%3.09%-46.81%303.70%

Growth

Compounded Sales Growth
10 Years:8%
5 Years:-3%
3 Years:10%
TTM:2%
Compounded Profit Growth
10 Years:9%
5 Years:-6%
3 Years:11%
TTM:33%
Stock Price CAGR
10 Years:10%
5 Years:-8%
3 Years:-1%
1 Year:47%
Return on Equity
10 Years:13%
5 Years:9%
3 Years:7%
Last Year:10%

Last Updated: April 17, 2024, 1:09 pm

Bliss GVS Pharma Ltd Balance Sheet

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Sep 2023
Equity Capital10101010101010101010101010
Reserves200248277327402476526636725798808873920
Borrowings45148173160132225118102126122109102100
Other Liabilities54165123166218311206157168147181171168
Total Liabilities3105715836627621,0238609051,0301,0771,1091,1571,197
Fixed Assets40168213234225305143146242234281379380
CWIP714094047022232
Investments1000000000284
Other Assets262402365428527714717712788840803768812
Total Assets3105715836627621,0238609051,0301,0771,1091,1571,197

Reserves and Borrowings Chart

Bliss GVS Pharma Ltd Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Cash from Operating Activity 36641381132891840476413534
Cash from Investing Activity -22-124-11-29-50-24948-79-40-45-103-6
Cash from Financing Activity 26110-8-42-40-10-7617-6-21-24-25
Net Cash Flow40-822-342330-10-220-293

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow26.00-37.00-102.00-57.0024.00-22.0079.0058.00-3.00-15.009.0015.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Debtor Days176225228222201116134187290293192187
Inventory Days29587069555055466411011694
Days Payable95212176165153100554775828679
Cash Conversion Cycle1117112112610267134186279321221202
Working Capital Days13513014616012576182180269319219221
ROCE %39%35%20%23%31%29%27%26%18%12%14%12%

Financial Efficiency Indicators Chart

Bliss GVS Pharma Ltd Share Holding Pattern

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023
Promoters33.31%33.31%33.24%33.19%33.14%33.14%34.51%34.55%34.46%35.04%35.12%35.06%
FIIs23.34%22.83%21.24%21.01%19.59%17.33%17.17%16.68%16.53%16.60%16.50%16.31%
DIIs5.74%6.72%6.72%6.67%6.66%6.66%6.65%6.64%6.63%6.63%6.62%6.61%
Public37.61%37.14%38.80%39.13%40.61%42.87%41.67%42.13%42.35%41.73%41.73%42.00%
No. of Shareholders15,42228,54339,99942,74241,08045,86646,32745,75344,98343,04142,18243,234

Shareholding Pattern Chart

No. of Shareholders

Bliss GVS Pharma Ltd Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)
Motilal Oswal S&P BSE Healthcare ETF5970.090.01

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 23Mar 22Mar 21Mar 20Mar 19
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)6.831.466.649.4311.99
Diluted EPS (Rs.)6.721.436.499.4311.99
Cash EPS (Rs.)9.163.908.8410.4613.15
Book Value[Excl.RevalReserv]/Share (Rs.)88.0881.6480.2772.7563.97
Book Value[Incl.RevalReserv]/Share (Rs.)88.0881.6480.2772.7563.97
Revenue From Operations / Share (Rs.)72.1672.0955.9666.8387.08
PBDIT / Share (Rs.)12.9714.4512.3015.7518.93
PBIT / Share (Rs.)11.1812.7810.6314.5318.06
PBT / Share (Rs.)10.185.2210.1012.5017.64
Net Profit / Share (Rs.)7.372.237.179.2312.28
NP After MI And SOA / Share (Rs.)6.801.456.649.4311.99
PBDIT Margin (%)17.9720.0421.9823.5721.73
PBIT Margin (%)15.4917.7218.9921.7420.74
PBT Margin (%)14.117.2418.0318.7020.25
Net Profit Margin (%)10.203.0912.8113.8114.10
NP After MI And SOA Margin (%)9.422.0111.8614.1113.77
Return on Networth / Equity (%)8.011.838.4713.2219.15
Return on Capital Employeed (%)12.0815.1312.5518.8126.70
Return On Assets (%)6.121.356.369.4513.67
Long Term Debt / Equity (X)0.040.020.040.050.05
Total Debt / Equity (X)0.110.120.120.140.14
Asset Turnover Ratio (%)0.530.590.470.500.53
Current Ratio (X)3.613.333.763.333.35
Quick Ratio (X)3.082.803.273.012.98
Inventory Turnover Ratio (X)2.963.712.733.142.94
Dividend Payout Ratio (NP) (%)7.3234.417.5212.7810.07
Dividend Payout Ratio (CP) (%)5.7915.986.0111.319.39
Earning Retention Ratio (%)92.6865.5992.4887.2289.93
Cash Earning Retention Ratio (%)94.2184.0293.9988.6990.61
Interest Coverage Ratio (X)13.0431.6023.0121.4744.23
Interest Coverage Ratio (Post Tax) (X)8.4021.4014.4215.3529.69
Enterprise Value (Cr.)770.70752.99990.811054.791860.20
EV / Net Operating Revenue (X)1.031.011.721.532.07
EV / EBITDA (X)5.705.037.816.499.53
MarketCap / Net Operating Revenue (X)0.981.071.761.512.07
Retention Ratios (%)92.6765.5892.4787.2189.92
Price / BV (X)0.830.971.261.412.87
Price / Net Operating Revenue (X)0.981.071.761.512.07
EarningsYield0.090.010.060.090.06

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value: ₹99.21

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

Overvalued: 11.42% compared to the current price ₹112

Intrinsic Value: ₹96.99

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators along with EPS growth.

Overvalued: 13.41% compared to the current price ₹112

Last 5 Year EPS CAGR: -2.24%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 23.83%, which is a positive sign.
  2. The company has higher reserves (555.08 cr) compared to borrowings (127.85 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (615.15 cr) and profit (116.77 cr) over the years.
  1. The stock has a high average Working Capital Days of 180.17, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 161.75, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Bliss GVS Pharma Ltd:
    1. Net Profit Margin: 10.20%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 12.08% (Industry Average ROCE: 20.33%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 8.01% (Industry Average ROE: 16.48%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 8.40
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 3.08
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. ✓ Stock P/E: 13.4 (Industry average Stock P/E: 19.82)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. ✓ Total Debt / Equity: 0.11
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Bliss GVS Pharma Ltd. is a Public Limited Listed company incorporated on 11/12/1984 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24230MH1984PLC034771 and registration number is 034771. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 636.36 Cr. and Equity Capital is Rs. 10.37 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
Pharmaceuticals102, Hyde Park, Saki Vihar Road, Mumbai Maharashtra 400072info@blissgvs.com
http://www.blissgvs.com
Management
NamePosition Held
Mr. S R VaidyaChairman & Ind.Director
Mr. Gagan Harsh SharmaManaging Director
Dr. Vibha Gagan SharmaWhole Time Director
Mrs. Shruti Vishal RaoWhole Time Director
Mr. Santosh L ParabIndependent Director
Mrs. Shilpa BhatiaIndependent Woman Director

FAQ

What is the latest fair value of Bliss GVS Pharma Ltd?

The latest fair value of Bliss GVS Pharma Ltd is 99.21.

What is the Market Cap of Bliss GVS Pharma Ltd?

The Market Cap of Bliss GVS Pharma Ltd is 1,175 Cr..

What is the current Stock Price of Bliss GVS Pharma Ltd as on 17 April 2024?

The current stock price of Bliss GVS Pharma Ltd as on 17 April 2024 is 112.

What is the High / Low of Bliss GVS Pharma Ltd stocks in FY 2024?

In FY 2024, the High / Low of Bliss GVS Pharma Ltd stocks is ₹150/70.8.

What is the Stock P/E of Bliss GVS Pharma Ltd?

The Stock P/E of Bliss GVS Pharma Ltd is 13.4.

What is the Book Value of Bliss GVS Pharma Ltd?

The Book Value of Bliss GVS Pharma Ltd is 88.8.

What is the Dividend Yield of Bliss GVS Pharma Ltd?

The Dividend Yield of Bliss GVS Pharma Ltd is 0.45 %.

What is the ROCE of Bliss GVS Pharma Ltd?

The ROCE of Bliss GVS Pharma Ltd is 11.8 %.

What is the ROE of Bliss GVS Pharma Ltd?

The ROE of Bliss GVS Pharma Ltd is 8.30 %.

What is the Face Value of Bliss GVS Pharma Ltd?

The Face Value of Bliss GVS Pharma Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Bliss GVS Pharma Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE